Our commitment is to turn our efforts into research, with passion, competence and boldness.
Take a closer look at our management team by clicking the single profiles.
Born in Milan in 1955, Sergio Dompé is an entrepreneur in the pharmaceutical and biotechnological industries and President of Dompé, a pharmaceutical group developing innovative therapeutic solutions for rare and orphan diseases.
He has awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010).
Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centres for diseases in Dompé’s main therapeutic fields.
In 2016, he funded and established Movendo, an innovative medical company sparkled by an idea by the Italian Institute of Technology: to develop the most advanced technologies at the service of mankind and products in the field of physical movement rehabilitation.
In 2004 he was awarded the “La Lombardia per il lavoro” prize, in recognition of his value as one of Lombardy’s most innovative entrepreneurs.
In 2016, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.), regularly awarded to those who distinguish themselves in the research field.
In 2017 he was awarded the Guido Carli prize.
Institutional offices held
- From 1998 to 2004: President of Assobiotec
- Since 2004, anchor investor in Philogen, a leader in the research and development of antibodies
- From 2005 to 2011: President of Farmindustria
- From 2006 to 2011: Chairman of the Evaluation Committee of the CNR (Consiglio Nazionale delle Ricerche, National Research Council).
- From 2007 to 2015: member of the Board of the IIT (Italian Institute of Technology) Foundation
- From 2014 to 2016: member of the Patent Experts Committee of the CNR
- From 2014 to 2016: member of the Board of Regency of the Bank of Italy (Milan office)
- Since 2015: member of the General Council of Confindustria as representative of Farmindustria
- Since 2016: Censor of the Bank of Italy (Milan office)
- Since 2019: Vice President of Assolombarda with delegated powers over Life Sciences
Chief Operating Officer
After graduating in Economics at "La Sapienza" University in Rome, she completed her studies with an MBA at Politecnico di Milano.
In 2005 she joined Bain & Company where she gained a consolidated and internationally recognized expertise in the healthcare sector.
She joined Dompé in 2018 as Chief Operating Officer (COO) and she’s in charge of leading the company's internationalization project, with an emphasis on biotechnology, following the FDA approval of the first therapy for neurotrophic keratitis.
The COO coordinates the company’s activities, with the strategic goal of providing patients with highly innovative solutions in response to unmet medical needs.
Chief Scientific Officer
With a degree in Medical Chemistry from The Sapienza University of Rome, Marcello is a member of the American Chemical Society since 1988 and the Italian Chemistry Society since 2006.
After a brief period as a university researcher, he joined Dompé as a team leader, followed by a period as Research Director and, since 2009, as a Chief Scientific Officer.
He leads Dompe’s Research and Development activities and pre-clinical and clinical drug development programs - from active ingredient identification to market authorization - including relationships with international regulatory authorities.
Marcello also holds a number of university teaching positions and maintains his scientific interests, with published work in over forty scientific journals.
He has also filed over thirty international patents.
Chief Financial Officer
Giuseppe Andreano joined Dompé in 2007.
Following a degree in Business Administration from Bocconi University in Milan, Giuseppe gained experience in administration and financial management with major multinational companies.
Giuseppe is Dompe’s Chief Financial Officer in charge of administration, budgets and financial control. He also manages IT and purchases.
Chief Industrial Officer
With a degree in Chemical Engineering and a Masters in Quality Management, Annaletizia also holds Six Sigma Black Belt certification.
With twenty years experience in the chemico-pharmaceutical industry, at the Sanofi plant in Scoppito, Italy, where roles have included responsibility for Industrial Technology, Manufacturing and Industrial Development and Production.
She was promoted to Director of Plant in 2010 and Chief Manufacturing Officer in 2018, responsible for managing the Group’s Manufacturing division at L'Aquila which manufactures solid and liquid-form pharmaceutical products, as well as biotechnological active ingredients with DNA recombinant technology.
Chief Compliance Officer
After graduating with a degree in Chemistry and Pharmaceutical Technology from the University of Bari, Amalia briefly worked as a laboratory assistant before joining the pharmaceutical industry, gaining experience with a number of national and international companies.
With experience as a Pharmaceutical Representative, in Quality Assurance (in distribution and production), she was also Country Quality Specialist for Amgen’s international team.
This was followed by the role of Healthcare Compliance Manager, initially for Italy and later for several other European countries.
Following this she joined Celgene Corporation in Switzerland as Senior Director, EMEA Healthcare Compliance and Audit.
Amalia became Dompe’s Chief Compliance Officer in 2018 in charge of implementing and managing our corporate compliance program.
Chief Commercial Officer, Primary Care
Davide graduated in Business Administration from Bocconi University in Milan. Since 2015, he has been managing Dompé’s Commercial Operations in Primary Care at national and international level.
Before taking on this role, he held a number of different marketing and sales positions within the company, focusing on the promotion and development of OTC and ethical drugs.